Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 187

Despite a wealth of knowledge gained in the past three decades concerning the molecular underpinnings of Alzheimer’s disease (AD), progress towards obtaining effective, disease modifying therapies has proven to be challenging. In this manner, numerous clinical trials targeting the production, aggregation, and toxicity of beta-amyloid, have failed to meet efficacy standards. This puts into question the beta-amyloid hypothesis and suggests that additional treatment strategies should be explored. The recent emergence of CRISPR/Cas9 gene editing as a relatively straightforward, inexpensive, and precise system has led to an increased interest of applying this technique in AD. CRISPR/Cas9 gene editing can be used as a direct treatment approach or to help establish better animal models that more faithfully mimic human neurodegenerative diseases. In this manner, this technique has already shown promise in other neurological disorders, such as Huntington’s disease. The purpose of this review is to examine the potential utility of CRISPR/Cas9 as a treatment option for AD by targeting specific genes including those that cause early-onset AD, as well as those that are significant risk factors for late-onset AD such as the apolipoprotein E4 (APOE4) gene.

Keywords: Alzheimer’s disease, CRISPR/Cas9, Gene editing, Treatment, Huntington’s disease, iPSC neurons.

Alzheimer’s Disease (AD) is a progressive and fatal neurodegenerative disorder that primarily affects older adults and is the most common cause of dementia [1]. Currently it afflicts 5.5 million Americans and that number is expected to triple by 2050. At the present time, it is the third leading cause of death behind heart disease and cancer, with an estimated 700,000 Americans ages65 years will have AD when they die [2]. In addition, the cost of the disease is substantial with $259 billion health care dollars going to manage the disease currently, and by the middle of the century costs are predicted to soar over $1.2 trillion, which will completely bankrupt the healthcare system in the USA [3]. Worldwide, 47 million people live with dementia and that number is projected to increase to more than 131 million by 2050 with an estimated worldwide cost of US $818 billion [4].

Read more | >

Every industry will be affected by quantum computing. They will alter the way business is done and the security systems in place which protect data, how we battle illnesses and create new materials, as well as how we tackle health and climate challenges.

As the race to build the first commercially functional quantum computer heats up, here we discuss a handful of the ways quantum computing will alter our world.

Read more | >

Biomedical Interventions For Substantial Global Health Concerns — Dr. Emilio Emini, Ph.D., CEO, Bill & Melinda Gates Medical Research Institute

Dr. Emilio A. Emini, Ph.D. is the CEO of the Bill & Melinda Gates Medical Research Institute (https://www.gatesmri.org/), a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited, and he leads the Institute’s research and development of novel products and interventions for diseases disproportionately impacting the world’s most vulnerable populations.

Before joining the Gates MRI, Dr. Emini served as director of the HIV and Tuberculosis program at the Bill & Melinda Gates Foundation, where he led the foundation’s efforts focused on accelerating the reduction in the incidence of HIV and TB in high-burden geographies, with the goal of achieving sustained epidemic control.

Continue reading “Dr. Emilio Emini, Ph.D. — CEO — Bill & Melinda Gates Medical Research Institute” | >

SHANGHAI, March 22 (Reuters) — Not a single country managed to meet the World Health Organization’s (WHO) air quality standard in 2021, a survey of pollution data in 6,475 cities showed on Tuesday, and smog even rebounded in some regions after a COVID-related dip.

The WHO recommends that average annual readings of small and hazardous airborne particles known as PM2.5 should be no more than 5 micrograms per cubic metre after changing its guidelines last year, saying that even low concentrations caused significant health risks.

But only 3.4% of the surveyed cities met the standard in 2021, according to data complied by IQAir, a Swiss pollution technology company that monitors air quality. As many as 93 cities saw PM2.5 levels at 10 times the recommended level.

Read more | >

A.I. is only beginning to show what it can do for modern medicine.

In today’s society, artificial intelligence (A.I.) is mostly used for good. But what if it was not?

Naive thinking “The thought had never previously struck us. We were vaguely aware of security concerns around work with pathogens or toxic chemicals, but that did not relate to us; we primarily operate in a virtual setting. Our work is rooted in building machine learning models for therapeutic and toxic targets to better assist in the design of new molecules for drug discovery,” wrote the researchers in their paper. “We have spent decades using computers and A.I. to improve human health—not to degrade it. We were naive in thinking about the potential misuse of our trade, as our aim had always been to avoid molecular features that could interfere with the many different classes of proteins essential to human life.”

Full Story:

Continue reading “An artificial intelligence invents 40,000 chemical weapons in just 6 hours” | >

New research from Griffith University has shown that a bacterium commonly present in the nose can sneak into the brain and set off a cascade of events that may lead to Alzheimer’s disease.

Associate Professor Jenny Ekberg and colleagues from the Clem Jones Centre for Neurobiology and Stem Cell Research at Menzies Health Institute Queensland and Griffith Institute for Drug Discovery, in collaboration with Queensland University of Technology, have discovered that the bacterium Chlamydia pneumoniae can invade the brain via the nerves of the nasal cavity.

Read more | >

Re-engineering clinical trials around participants — katie baca-motes, co-founder, scripps research digital trials center, scripps research.

Katie Baca-Motes, MBA, (https://www.scripps.edu/science-and-medicine/translational-i…aca-motes/) is Senior Director, Strategic Initiatives at the Scripps Research Translational Institute, and Co-Founder of the Scripps Research Digital Trials Center (https://digitaltrials.scripps.edu/).

Katie leads various initiatives, including launching their new Digital Trials Center, focusing on expanding the institute’s portfolio of decentralized clinical trial initiatives including: DETECT, a COVID-19 research initiative, PowerMom, a maternal health research program and PROGRESS, an upcoming T2 Diabetes/Precision Nutrition program, as well as overseeing the institute’s role in the NIH “All of Us” Research Program as a Participant Center.

Continue reading “Katie Baca-Motes — Co-Founder, Scripps Research Digital Trials Ctr — Re-Engineering Clinical Trials” | >

The last-mile mobile health services provider, DocGo, has announced the delivery of its new all-electric, zero-emissions ambulance that eliminates the pollution of a standard gasoline ambulance.

The all–electric vehicle will be the first of its kind to be registered in the U.S. The new vehicle has been developed in partnership with Leader Emergency Vehicles in South El Monte, CA, and marks the first step towards “Zero Emission,” the company’s latest sustainability mission to have an all-electric fleet by 2032.

DocGo stated that its new vehicle produces 1/10th of the pollutants expelled by a standard gas-powered ambulance. In addition to being less harmful to the planet, the electric ambulance has the potential to lower patient transportation costs due to lower fuel costs and maintenance needs.

Read more | >

Synopsis: No sentient being in the evolutionary history of life has enjoyed good health as defined by the World Health Organization. The founding constitution of the World Health Organization commits the international community to a daringly ambitious conception of health: “a state of complete physical, mental and social wellbeing”. Health as so conceived is inconsistent with evolution via natural selection. Lifelong good health is inconsistent with a Darwinian genome. Indeed, the vision of the World Health Organization evokes the World Transhumanist Association. Transhumanists aspire to a civilization of superhappiness, superlongevity and superintelligence; but even an architecture of mind based on information-sensitive gradients of bliss cannot yield complete well-being. Post-Darwinian life will be sublime, but “complete” well-being is posthuman – more akin to Buddhist nirvana. So the aim of this talk is twofold. First, I shall explore the therapeutic interventions needed to underwrite the WHO conception of good health for everyone – or rather, a recognisable approximation of lifelong good health. What genes, allelic combinations and metabolic pathways must be targeted to deliver a biohappiness revolution: life based entirely on gradients of well-being? How can we devise a more civilized signalling system for human and nonhuman animal life than gradients of mental and physical pain? Secondly, how can genome reformists shift the Overton window of political discourse in favour of hedonic uplift? How can prospective parents worldwide – and the World Health Organization – be encouraged to embrace genome reform? For only germline engineering can fix the problem of suffering and create a happy biosphere for all sentient beings.

The End of Suffering – Genome Reform and the Future of Sentience – David Pearce

Read more | >